Activity Report for Quarter Ended September 30, 2026 (Appendix 4C)
NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided its activity report for the first fiscal quarter ended September 30, 2026.
Covered in this story
Call it yourself
No calls on $MESO yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Mesoblast →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.